.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EX27_Capivasertib.Capivasertib .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EX27_Capivasertib.Capivasertib| name: | Capivasertib |
| ATC code: | L01EX27 | route: | oral |
| n-compartments | 2 |
Capivasertib is an oral, selective pan-AKT kinase inhibitor developed for the treatment of various cancers, including breast cancer. It is currently approved in combination with fulvestrant for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in adults who have received prior endocrine therapy.
Population pharmacokinetics in adult cancer patients after oral administration; values based on phase I/II clinical trials.
Fernandez-Teruel, C, et al., & Zhou, D (2024). Population Pharmacokinetics of Capivasertib in Patients with Advanced or Metastatic Solid Tumours. Clinical pharmacokinetics 63(8) 1191–1204. DOI:10.1007/s40262-024-01407-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/39127854
Miller, C, et al., & Cullberg, M (2024). Pharmacokinetic study of capivasertib and the CYP3A4 substrate midazolam in patients with advanced solid tumors. Cancer chemotherapy and pharmacology 94(2) 223–235. DOI:10.1007/s00280-024-04667-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38643311